- Home
- NPCE
NPCE
Neuropace Inc.
as 11-03-2025 4:00pm EST
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 328.8M | IPO Year: | 2021 |
| Target Price: | $16.67 | AVG Volume (30 days): | 121.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.03 - $18.98 | Next Earning Date: | 11-04-2025 |
| Revenue: | $88,570,000 | Revenue Growth: | 23.32% |
| Revenue Growth (this year): | 22.13% | Revenue Growth (next year): | 6.07% |
Latest Neuropace Inc. News
NPCE Breaking Stock News: Dive into NPCE Ticker-Specific Updates for Smart Investing
GuruFocus.com
a day ago
NeuroPace Inc (NPCE) Q3 2025 Earnings Report Preview: What to Look For
Business Wire
13 days ago
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
Simply Wall St.
2 months ago
NeuroPace, Inc.'s (NASDAQ:NPCE) Intrinsic Value Is Potentially 99% Above Its Share Price
GlobeNewswire
4 months ago
NeuroPace Announces Strategic CFO Transition
Insider Monkey
5 months ago
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey
MT Newswires
5 months ago
NeuroPace Secures $75 Million Credit Facility From MidCap Financial
GlobeNewswire
5 months ago
NeuroPace Secures Up to $75 Million in Debt Financing
Insider Monkey
5 months ago
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating
Compare NPCE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NPCE Neuropace Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.